AR092969A1 - PHARMACEUTICAL FORMULATIONS AND PRODUCTION PROCESS OF PHARMACEUTICAL FORMULATIONS - Google Patents

PHARMACEUTICAL FORMULATIONS AND PRODUCTION PROCESS OF PHARMACEUTICAL FORMULATIONS

Info

Publication number
AR092969A1
AR092969A1 ARP130103677A ARP130103677A AR092969A1 AR 092969 A1 AR092969 A1 AR 092969A1 AR P130103677 A ARP130103677 A AR P130103677A AR P130103677 A ARP130103677 A AR P130103677A AR 092969 A1 AR092969 A1 AR 092969A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical formulation
pharmaceutical formulations
formulation according
production process
adjuvant
Prior art date
Application number
ARP130103677A
Other languages
Spanish (es)
Inventor
Coraucci Neto Dolivar
Original Assignee
Ouro Fino Participações E Empreendimentos S/A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ouro Fino Participações E Empreendimentos S/A filed Critical Ouro Fino Participações E Empreendimentos S/A
Publication of AR092969A1 publication Critical patent/AR092969A1/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Formulación farmacéutica caracterizada por comprender: a) fase acuosa conteniendo: del 30 - 40% de antígeno; del 0 al 10% de vehículo acuoso; del 0 al 1% de adyuvante; b) fase oleosa conteniendo: del 50% al 70% de vehículo oleoso; del 0,01% al 20% de tensoactivo. Reivindicación 2: Formulación farmacéutica, de acuerdo con la reivindicación 1, caracterizada por comprender antígeno elegido del grupo que comprende Virus Inactivado O1 Campos, A24 Cruzeiro, C3 Indaial. Reivindicación 3: Formulación farmacéutica, de acuerdo con la reivindicación 1, caracterizada por comprender saponina como adyuvante. Reivindicación 4: Formulación farmacéutica, de acuerdo con la reivindicación 1, caracterizada por comprender aceite mineral como vehículo acuoso. Reivindicación 5: Formulación farmacéutica, de acuerdo con la reivindicación 1, caracterizada por comprender el 1 al 3% de tensoactivo polimérico. Reivindicación 6: Formulación farmacéutica, de acuerdo con la reivindicación 1, caracterizada por comprender tensoactivo polimérico derivado de Dimethicone.Claim 1: Pharmaceutical formulation characterized by comprising: a) aqueous phase containing: 30-40% antigen; 0 to 10% aqueous vehicle; 0 to 1% adjuvant; b) oil phase containing: 50% to 70% oil vehicle; 0.01% to 20% surfactant. Claim 2: Pharmaceutical formulation according to claim 1, characterized in that it comprises antigen chosen from the group comprising Inactivated Virus O1 Campos, A24 Cruzeiro, C3 Indaial. Claim 3: Pharmaceutical formulation according to claim 1, characterized by comprising saponin as an adjuvant. Claim 4: Pharmaceutical formulation according to claim 1, characterized in that it comprises mineral oil as an aqueous vehicle. Claim 5: Pharmaceutical formulation according to claim 1, characterized in that it comprises 1 to 3% of polymeric surfactant. Claim 6: Pharmaceutical formulation according to claim 1, characterized in that it comprises polymeric surfactant derived from Dimethicone.

ARP130103677A 2012-10-16 2013-10-10 PHARMACEUTICAL FORMULATIONS AND PRODUCTION PROCESS OF PHARMACEUTICAL FORMULATIONS AR092969A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102012026503A BR102012026503B1 (en) 2012-10-16 2012-10-16 pharmaceutical formulations and pharmaceutical formulation production process

Publications (1)

Publication Number Publication Date
AR092969A1 true AR092969A1 (en) 2015-05-06

Family

ID=50548912

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103677A AR092969A1 (en) 2012-10-16 2013-10-10 PHARMACEUTICAL FORMULATIONS AND PRODUCTION PROCESS OF PHARMACEUTICAL FORMULATIONS

Country Status (4)

Country Link
AR (1) AR092969A1 (en)
BR (1) BR102012026503B1 (en)
CO (1) CO6930059A1 (en)
UY (1) UY35077A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102021012953A2 (en) 2021-06-29 2023-01-10 Fabp Biotech Desenvolvimento Em Biotecnologia Ltda. COMPOSITION OF VETERINARY VACCINE AGAINST HELMINTHS, METHOD FOR TREATMENT AND PREVENTION OF INFECTION CAUSED BY HELMINTHS AND USE

Also Published As

Publication number Publication date
UY35077A (en) 2014-05-30
BR102012026503A2 (en) 2014-06-17
BR102012026503B1 (en) 2016-08-09
CO6930059A1 (en) 2014-04-28

Similar Documents

Publication Publication Date Title
AR102657A1 (en) COMPOSITION TO TREAT FABRICS
CR20150189A (en) THERAPEUTIC NANOPARTICLES THAT INCLUDE A THERAPEUTIC AGENT AND METHODS TO PERFORM AND USE THEM
CO7160016A2 (en) Composition comprising fermentation products of bacillus subtilis
CL2016001154A1 (en) Compositions to prevent or treat allergies in infants from or fed by non-secretory mothers.
CR20150287A (en) PHARMACEUTICAL COMPOSITION WITH IMPROVED BIODISPONIBILITY
MX362655B (en) Cosmetic compositions.
BR112014026109A2 (en) a hair care composition comprising metatetised polyol unsaturated esters
BR112014029774A2 (en) use of n-methyl-n-acylglucamines as thickening agents in surfactant solutions
PE20150200A1 (en) FORMULATION OF ANTIBODIES
IN2014DN09936A (en)
BR112015029254A2 (en) low ph detergent composition comprising nonionic surfactants
ECSP16062173A (en) HETEROARYL BUTANOIC ACID DERIVATIVES AS LTA4H INHIBITORS
BR112015004515A2 (en) immunogenic composition
GT201600066A (en) COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF GEN ALAS1
BR112015023523B8 (en) PHARMACEUTICAL COMPOSITIONS AND SINGLE DOSAGE FORM CONTAINER
BR112018011504A2 (en) thrombin microcapsules
CL2015001562A1 (en) Method to obtain a mycoplasma vaccine.
CL2014002875A1 (en) Process for producing a detergent granule, comprising at least 40% by weight of anionic surfactant; a detergent and detergent granule composition comprising said granule
BR112015010271A8 (en) Comicronization product, process for the preparation of a comicronization product, pharmaceutical composition and its uses
CO6590210A1 (en) Complex obtained from mixtures of hyaluronic acid or a salt thereof and chondroitin sulfate
BR112015030135A2 (en) oligohydroxy carboxylic acid esters and their use
CO2017007316A2 (en) Pharmaceutical formulation
BR112013019924A8 (en) COMPOSITIONS FOR ORAL CARE
BR112014029264A2 (en) microcapsules containing an active oxidiser, and a process for the preparation thereof
MX368582B (en) Gardenia extract for colouring the skin.

Legal Events

Date Code Title Description
FB Suspension of granting procedure